The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
